BMYMP News and Press, Bristol-Myers Squibb $2Pr From 04/13/22

Historically, PPH generated a steady total return with a low yield up to 2 percent. PPH’s price multiples are considerably lower than its peers and index despite strong earnings and stable historical price growth. Half of PPH’s portfolio has been extremely productive...

The Financial Prophet's All-Weather Portfolio "AWP" delivered another solid quarter in Q1. Diversification, adjustments around pivotal points in the market, and effective hedging helped optimize the portfolio's returns. However, not everything worked out as well as it could have. ...

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. For further details see: Dividend Champion, Contender, An...

First patient dosed in phase 1/2 ADventure study which is using BBP-631 for the treatment of patients with congenital adrenal hyperplasia; results from the study expected 2nd half of 2022. An SHP2 inhibitor BBP-398 is being explored in combination with Amgen's LUMAKRAS, along wit...

An analysis of global supply chains and commodity markets in the presence of significant kinetic warfare. An overview of why sovereign reserve practices may start to shift towards more diversification and neutral reserve assets. Examples of three attractive stocks for the long run...

Halvorsen's 13F portfolio value decreased from $36.04B to $34.49B this quarter. The number of positions increased from 96 to 107. Viking Global added Twilio, Workday, and Aon plc while dropping Fidelity National Information Services and Snowflake. The top three positions are Ginkg...

Bristol-Myers Squibb Co (BMY) Barclays Global Healthcare Conference March 16, 2022, 13:35 ET Company Participants Samit Hirawat - EVP & Chief Medical Officer, Global Drug Development Conference Call Participants Carter Gould - Barclays Bank Presentation Carter Gould Good afternoon, and we...

On January 28th, I published a Perfect Portfolio (backbone) for Turbulent Times. Only a few weeks later the world got shocked by how events unfolded in Ukraine. The situation in Ukraine is horrible and I hope they find a solution soon to stop all the violence and suffering! The fi...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Stock and REIT indexes remain below their 200-day moving averages, and investor sentiment is decidedly fearful. Volatility is returning to the market, and with it comes opportunity. We present two fast-growing REITs that are attractively valued and well-positioned to handle rising...